DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lipegfilgrastim
Lipegfilgrastim
2018 Annual Report on Eudravigilance for the European Parliament, the Council and the Commission Reporting Period: 1 January to 31 December 2018
The Impact of Biosimilar Competition in Europe December 2020
2020, Vol. 16, Number 1, 1–40
Australian Public Assessment for Lipegfilgrastim (Rbe)
Colony Stimulating Factors
The Impact of Biosimilar Competition in Europe Contents
Pam378 Lipegfilgrastim Lonquex Neutropenia
INN Working Document 05.179 Update 2011
1 the PREVENTION of ORAL SIDE EFFECTS of CANCER TREATMENT VOLUME I of II a Thesis Submitted to the University of Manchester
Granulocyte Colony Stimulating Factors (G-CSF) Medical Policy No
Evaluation of Effectiveness of Granulocyte-Macrophage Colony-Stimulating Factor Therapy to Cancer Patients After Chemotherapy: a Meta-Analysis
(INN) for Biological and Biotechnological Substances
Download Report
(G-Csfs) (Filgrastim, Lenograstim, Lipegfilgrastim and Pegfilgrastim): New Warning Regarding Aortitis
Publication Only
Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England
Lonquex 6 Mg Solution for Injection in Pre-Filled Syringe
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Top View
Supplemental Material 1
The Impact of Biosimilar Competition June 2016 the Impact of Biosimilar Competition Introduction
The Impact of Biosimilar Competition in Europe Contents
Lonquex, INN-Lipegfilgrastim
Lonquex, INN-Lipegfilgrastim
The Incidence and Clinical Features of Pegylated Filgrastim-Induced Acute
Complications of Cancer Chemotherapy
Fulphila, INN-Pegfilgrastim
HEMATOPOIETIC AGENTS;GROWTH FACTORS,MINERALS and VITAMINS Phr.Volkan KAHRAMAN HGF’S
Product Information for Auspar Lonquex Lipegfilgrastim (Rbe) Teva Pharma Australia Pty Ltd, PM- 2014-03142-1-4 Final 23 February 2016
Lonquex, INN-Lipegfilgrastim
Back Matter (PDF)
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care That Enables Cure
Cost-Effectiveness and Budgetary Impact of Lipegfilgrastim for The
Abstract Book
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Guideline for the Use of Granulocyte-Colony Stimulating Factor (G-CSF) in Adult Oncology and Haematology Patients
(INN) for Biological and Biotechnological Substances
AR Annexes 2017 Collated
3.2.2 Granulocyte-Colony Stimulating Factors, Pulmonary Haemorrhage
Study Protocol
Summary Report of Benefit-Risk Assessment
Role of Lipegfilgrastim in the Management of Chemotherapy-Induced Neutropenia
2017/19 Pbr Excluded Drugs: Proposed GMMMG Advisory Position [Appendix 3]
Annexes to the Annual Report of the European Medicines Agency 2020
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Publication Agenda CHMP 07-10 December 2020
Efficacy and Safety of Lipegfilgrastim Versus Pegfilgrastim